Treatment of the severe CRS and neurotoxicity has been focused on blocking the IL-6 with anti-IL-6 antibody tocilizumab, which does not impact the functionality of the CAR T-cells [29]. This evidence concerns the gene IL6 and congenital rubella syndrome.